A Phase 3 interventional study of Ambroxol and Placebo in Pharyngitis, sponsored by Boehringer Ingelheim. Completed at 4 sites in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-11.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this trial is to investigate the efficacy and tolerance of Ambroxol lozenges 20 mg in the treatment of sore throat in patients with acute viral pharyngitis.
Male and female ambulant patients complaining of a sore throat caused by acute viral pharyngitis. Every patient may be included in the trial only once. A total of 250 male and female ambulant patients between the ages of 18 and 65 years will be enrolled. Approximately 8 centers will be recruited each enrolling approximately 30-32 patients.
Study Hypothesis:
The two-sided test hypothesis, that the results of the active treatment group with 20 mg Ambroxol and the placebo group do not differ with regard to the primary endpoint (null hypothesis (H0) will be tested against the alternative (H1) that they are not equal.
Comparison(s):
PRIMARY ENDPOINT:
Indication of pain on the VRS (PI)-verbal rating scale (pain intensity)-in the first 3 hours (the patient rates his/her pain on a six-point verbal rating scale).
SECONDARY ENDPOINT (S):
227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.
This study's enrollment of 249 is above the median of 144 across 189 interventional studies indexed under Pharyngitis.
Browse Pharyngitis studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Ambroxol
Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline
The calculation will be based on the pain intensity (PI) assessment by the patient before and then at (pain intensity difference at 30 minutes (PID30)), (pain intensity difference at 60 minutes (PID60)), (pain intensity difference at 120 minutes (PID120)) and (pain intensity difference at 180 minutes (PID180)) after the 1st lozenge. Using the difference in PI from pre-dose baseline for each time point subsequent to dosing, the SPIDnorm will be calculated as SPIDnorm = (30\*PID30 + 30\*PID60 + 60\*PID120 + 60\*PID180)/(180\*PI (baseline)) The patient rates the intensity of his sore throat pain on a 6-point Verbal Rating Scale (VRS) pain intensity (PI) before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.
Time frame: pre-dose baseline and 30, 60, 120, and 180 minutes
Pain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge
Pain intensity (PI) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. The patient rates the intensity of his sore throat condition on a 6-point rating scale \[VRS(PI)-verbal rating scale (pain intensity)\] before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain. Adjusted Mean (Standard Error) are presented for this outcome measure.
Time frame: 0.5, 1, 2 and 3 hours
Pain Intensity Difference From Pre-dose Baseline (PID) as Rated on a 6-point Verbal Rating Scale (VRS) by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge
Pain intensity difference from pre-dose baseline (PID) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. Adjusted Mean (Standard Error) are presented for this outcome measure.
Time frame: pre-dose baseline and 0.5, 1, 2 and 3 hours
Assessment of Redness of the Pharyngeal Mucosa by the Investigator on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation
Assessment of redness of the pharyngeal mucosa by the investigator on a 5-point VRS (normal, slightly red, clearly red, very red, severe inflammation) at pre-dose baseline and at the end-of-study evaluation.
Time frame: Day 1 and Day 2
Assessment of Patients' Assessment of Effectiveness on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation
Assessment of Patients' Assessment of Effectiveness on a 5-point VRS ("very good", "good", "neither good nor poor", "not very good", "not at all good") at pre-dose baseline and at the end-of-study evaluation
Time frame: Day 1 and Day 2
Male or female outpatients, 18 to 65 years of age, suffering from acute viral pharyngitis and throat pain of at least severe intensity were to enter the trial.
| Milestone | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| Started | 124 | 125 |
| Completed | 124 | 124 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
The calculation will be based on the pain intensity (PI) assessment by the patient before and then at (pain intensity difference at 30 minutes (PID30)), (pain intensity difference at 60 minutes (PID60)), (pain intensity difference at 120 minutes (PID120)) and (pain intensity difference at 180 minutes (PID180)) after the 1st lozenge. Using the difference in PI from pre-dose baseline for each time point subsequent to dosing, the SPIDnorm will be calculated as SPIDnorm = (30\*PID30 + 30\*PID60 + 60\*PID120 + 60\*PID180)/(180\*PI (baseline)) The patient rates the intensity of his sore throat pain on a 6-point Verbal Rating Scale (VRS) pain intensity (PI) before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.
| ratio | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline | -0.40 ± 0.020 | -0.34 ± 0.020 |
Pain intensity (PI) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. The patient rates the intensity of his sore throat condition on a 6-point rating scale \[VRS(PI)-verbal rating scale (pain intensity)\] before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain. Adjusted Mean (Standard Error) are presented for this outcome measure.
| score on a scale | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| 30 minutes | 2.9 ± 0.08 | 3.1 ± 0.07 |
| 60 minutes | 2.6 ± 0.08 | 2.8 ± 0.08 |
| 120 minutes | 2.3 ± 0.10 | 2.7 ± 0.09 |
| 180 minutes | 2.2 ± 0.10 | 2.5 ± 0.10 |
Pain intensity difference from pre-dose baseline (PID) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. Adjusted Mean (Standard Error) are presented for this outcome measure.
| score on a scale | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| 30 minutes | -1.1 ± 0.08 | -1.0 ± 0.07 |
| 60 minutes | -1.4 ± 0.08 | -1.2 ± 0.08 |
| 120 minutes | -1.8 ± 0.10 | -1.4 ± 0.09 |
| 180 minutes | -1.9 ± 0.10 | -1.6 ± 0.10 |
Assessment of redness of the pharyngeal mucosa by the investigator on a 5-point VRS (normal, slightly red, clearly red, very red, severe inflammation) at pre-dose baseline and at the end-of-study evaluation.
| percentage of participants | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| Day 1_Normal | 0.0 | 0.8 |
| Day 1_Slightly red | 12.1 | 12.8 |
| Day 1_ Clearly red | 53.2 | 50.4 |
| Day 1_Very red | 29.8 | 32.0 |
| Day 1_Severe inflammation | 4.8 | 4.0 |
| Day 2_Normal | 12.1 | 10.5 |
| Day 2_Slightly red | 66.9 | 66.9 |
| Day 2_Clearly red | 18.5 | 21.8 |
| Day 2_Very red | 2.4 | 0.8 |
| Day 2_Severe inflammation | 0.0 | 0.0 |
Assessment of Patients' Assessment of Effectiveness on a 5-point VRS ("very good", "good", "neither good nor poor", "not very good", "not at all good") at pre-dose baseline and at the end-of-study evaluation
| percentage of participants | Ambroxol Lozenges 20 mg | Placebo |
|---|---|---|
| Day 1_Very good | 13.7 | 8.0 |
| Day 1_Good | 58.1 | 52.0 |
| Day 1_Neither good nor poor | 19.4 | 18.4 |
| Day 1_Not very good | 6.5 | 16.0 |
| Day 1_Not at all good | 2.4 | 5.6 |
| Day 2_Very good | 24.3 | 14.2 |
| Day 2_Good | 56.8 | 52.2 |
| Day 2_Neither good nor poor | 14.4 | 16.8 |
| Day 2_Not very good | 3.6 | 13.3 |
| Day 2_Not at all good | 0.9 | 3.5 |
Collected over From drug administration until end of the treatment, up to 2 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ambroxol Lozenges 20 mg | 0/124 (0%) | 0/124 (0%) | 0/124 (0%) |
| Placebo | 0/125 (0%) | 0/125 (0%) | 0/125 (0%) |
Full Analysis Set (FAS): FAS, which included all patients * who were randomized, * who took at least the first lozenge, * who had Pain Intensity (PI) data of baseline.
| Age, Continuous(years) | Ambroxol Lozenges 20 mg | Placebo | Total |
|---|---|---|---|
| Mean | 36.0 ± 12.2 | 38.4 ± 13.0 | 37.2 ± 12.7 |
| Sex: Female, Male(Participants) | Ambroxol Lozenges 20 mg | Placebo | Total |
|---|---|---|---|
| Female | 67 | 71 | 138 |
| Male | 57 | 54 | 111 |
Ran from Aug 2007 to primary completion in Jan 2008, 5 months.
Results were first posted in Jul 2019, 11 years 6 months after primary completion. A results delay was requested in Apr 2014.
Of 13 phase 3 interventional studies under Pharyngitis, half reached primary completion within 3 months of starting (the median); a quarter within 2 and three quarters within 6. This study's 5 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ambroxol